Last reviewed · How we verify
TAS-120
TAS-120 is a fibroblast growth factor receptor (FGFR) inhibitor that blocks FGFR signaling to suppress tumor cell growth.
TAS-120 is a fibroblast growth factor receptor (FGFR) inhibitor that blocks FGFR signaling to suppress tumor cell growth. Used for Cholangiocarcinoma with FGFR2 fusion or rearrangement, Other FGFR-altered solid tumors.
At a glance
| Generic name | TAS-120 |
|---|---|
| Also known as | Futibatinib |
| Sponsor | Taiho Oncology, Inc. |
| Drug class | FGFR inhibitor |
| Target | FGFR (Fibroblast Growth Factor Receptor) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
TAS-120 is a selective, irreversible FGFR inhibitor that covalently binds to FGFR kinase domains, preventing downstream signaling through the MAPK and PI3K pathways. This mechanism is particularly relevant in cancers driven by FGFR alterations, including FGFR fusions, amplifications, and mutations. By inhibiting FGFR activity, TAS-120 suppresses proliferation of FGFR-dependent tumor cells.
Approved indications
- Cholangiocarcinoma with FGFR2 fusion or rearrangement
- Other FGFR-altered solid tumors
Common side effects
- Hyperphosphatemia
- Diarrhea
- Fatigue
- Nausea
- Stomatitis
- Nail toxicity
Key clinical trials
- Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy. (PHASE2, PHASE3)
- Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements
- European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors (PHASE1, PHASE2)
- Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma (PHASE2)
- Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement (PHASE2)
- Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors (PHASE2)
- Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy (PHASE2)
- Molecular Profiling of Advanced Soft-tissue Sarcomas (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |